ATE237324T1 - Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen - Google Patents

Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen

Info

Publication number
ATE237324T1
ATE237324T1 AT95909482T AT95909482T ATE237324T1 AT E237324 T1 ATE237324 T1 AT E237324T1 AT 95909482 T AT95909482 T AT 95909482T AT 95909482 T AT95909482 T AT 95909482T AT E237324 T1 ATE237324 T1 AT E237324T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
compositions
neuroprotective pharmaceutical
effective
dexanabinol derivatives
Prior art date
Application number
AT95909482T
Other languages
German (de)
English (en)
Inventor
Raphael Mechoulam
Emil Pop
Mordechai Sokolovsky
Yoel Kloog
Anat Biegon
Original Assignee
Univ Ramot
Yissum Res Dev Co
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot, Yissum Res Dev Co, Pharmos Corp filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE237324T1 publication Critical patent/ATE237324T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT95909482T 1994-02-07 1995-02-06 Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen ATE237324T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/192,886 US5521215A (en) 1989-11-07 1994-02-07 NMDA-blocking pharmaceuticals
PCT/US1995/001470 WO1995020958A1 (en) 1994-02-07 1995-02-06 Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE237324T1 true ATE237324T1 (de) 2003-05-15

Family

ID=22711431

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909482T ATE237324T1 (de) 1994-02-07 1995-02-06 Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen

Country Status (10)

Country Link
US (1) US5521215A (enExample)
EP (1) EP0765160B1 (enExample)
JP (1) JPH09511493A (enExample)
AT (1) ATE237324T1 (enExample)
AU (1) AU690221B2 (enExample)
CA (1) CA2183466A1 (enExample)
DE (1) DE69530389T2 (enExample)
IL (1) IL112572A0 (enExample)
SG (1) SG49625A1 (enExample)
WO (1) WO1995020958A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
WO1998013046A1 (en) 1996-09-27 1998-04-02 Guilford Pharmaceuticals Inc. Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
DE19706903A1 (de) * 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
AU743788B2 (en) * 1997-05-07 2002-02-07 Unimed Pharmaceuticals, Inc. Method of improving disturbed behavior and elevating mood in humans
US6380261B1 (en) * 1997-06-30 2002-04-30 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
US6110139A (en) * 1997-10-21 2000-08-29 Loubser; Paul Gerhard Retrograde perfusion monitoring and control system
WO1999025350A1 (en) * 1997-11-14 1999-05-27 Alcon Laboratories, Inc. Treatment of diabetic retinopathy
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
EP1071419B1 (en) * 1998-04-21 2007-07-25 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Cannabinoids as antioxidants and neuroprotectants
CA2340445A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
WO2001028329A1 (en) 1999-10-18 2001-04-26 University Of Connecticut Peripheral cannabinoid receptor (cb2) selective ligands
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
CA2411585A1 (en) * 2000-06-22 2001-12-27 Pharmos Corporation Novel non-psychotropic cannabinoids
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
EP1785417A3 (en) * 2000-06-22 2007-08-01 Pharmos Corporation Novel non-psychotropic cannabinoids
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US7329651B2 (en) * 2001-01-26 2008-02-12 University Of Connecticut Cannabimimetic ligands
WO2002060447A1 (en) 2001-01-29 2002-08-08 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
EP1372638B1 (en) * 2001-04-06 2009-11-04 The Board Of Trustees Of The University Of Illinois Cannabinoids for the treatment of breathing disorders during sleep
WO2003005960A2 (en) * 2001-07-13 2003-01-23 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
WO2003035005A2 (en) * 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
US7029918B2 (en) * 2002-01-25 2006-04-18 Roche Diagnostics Operations, Inc. Water-soluble derivatives of lipophilic drugs
AU2003265663A1 (en) 2002-08-23 2004-03-11 University Of Connecticut Keto cannabinoids with therapeutic indications
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
WO2004021974A2 (en) * 2002-09-05 2004-03-18 Pharmos Corporation Non-psychotropic cannabinoids for prevention of cognitive impairment
EP1567513A2 (en) * 2002-12-04 2005-08-31 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical copositions
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
EP2578561A1 (en) * 2005-09-29 2013-04-10 Albany Molecular Research, Inc. Processes for the production of cannabidiol derivatives and intermediates thereof
DK2176208T3 (en) * 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
MA40498A (fr) * 2014-09-02 2021-05-19 Texas A & M Univ Sys Méthode de traitement de l'intoxication par organophosphates
US20170038184A1 (en) 2015-08-06 2017-02-09 Charles E. Ankner Formulation delivery system
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
CN110996926A (zh) 2017-07-20 2020-04-10 耶路撒冷希伯来大学伊萨姆研究开发有限公司 用于将亲脂性化合物递送进入和/或穿过皮肤的药物膜组合物
CN111278425B (zh) 2017-09-11 2024-06-11 耶路撒冷希伯来大学伊萨姆研究开发有限公司 用于向脑部经鼻给药药物和用于全身作用的组合物和方法
US20200345656A1 (en) 2017-11-29 2020-11-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cannabinoids compositions and methods
EP3873436A1 (en) 2018-11-04 2021-09-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Orally administrable cannabinoids-containing compositions and methods
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464695A (en) * 1974-06-24 1977-02-16 Smithkline Corp Dibenzo-b,c-pyrans and pharmaceutical compositions thereof
IL48824A (en) * 1976-01-12 1980-05-30 Yissum Res Dev Co Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4133819A (en) * 1977-06-17 1979-01-09 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
US4209520A (en) * 1977-06-17 1980-06-24 Pfizer Inc. Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
IL80411A (en) * 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
SG49625A1 (en) 1998-06-15
EP0765160B1 (en) 2003-04-16
DE69530389T2 (de) 2004-03-25
EP0765160A1 (en) 1997-04-02
DE69530389D1 (de) 2003-05-22
EP0765160A4 (enExample) 1997-04-09
JPH09511493A (ja) 1997-11-18
AU1743395A (en) 1995-08-21
US5521215A (en) 1996-05-28
AU690221B2 (en) 1998-04-23
CA2183466A1 (en) 1995-08-10
IL112572A0 (en) 1995-05-26
WO1995020958A1 (en) 1995-08-10

Similar Documents

Publication Publication Date Title
DE69530389D1 (de) Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen
EP1299374A4 (en) NEW NON PSYCHOTROPICAL CANNABINOIDS
BG101118A (en) Therapeutical compounds
DE69636308D1 (de) Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
ATE203019T1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n- disubstituierte-amino-3,4-dihydro-2h-1- benzopyrane
EE9800080A (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
SE9604786D0 (sv) New compounds
BR9909358A (pt) Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito
ATE119520T1 (de) Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
DE69531098D1 (de) Piperidine und pyrrolidine
AU5225498A (en) Biaromatic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
CA2215470A1 (fr) Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
AU2030497A (en) Propynyl or dienyl biaromatic compounds
DK0825197T3 (da) Nye 6-hydroxy- og 6-oxo-androstanderivater, der er aktive i forhold til det cardiovaskulære system, og farmaceutiske præpar
EP1736470A3 (en) Pyrimidine derivatives as CB2 cannabinoid receptor modulators
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
MXPA02003731A (es) Derivados novedosos de acido fusidico.
AU7076494A (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
EP1785417A3 (en) Novel non-psychotropic cannabinoids
PT986390E (pt) Composicoes farmaceuticas que contem cicloridrato de cinchonina
BR9813098A (pt) Uso de glicosaminoglicans, preparação farmacêutica, e, combinaçào
MX9709684A (es) Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties